10x Genomics, Inc. (NASDAQ: TXG) saw its stock surge 5.47% in after-hours trading on Thursday, following the release of its impressive second-quarter 2025 financial results and the announcement of a strategic acquisition. The biotechnology company significantly outperformed analyst expectations, demonstrating robust growth and a return to profitability.

The company reported quarterly earnings of $0.28 per share, drastically surpassing the analyst consensus estimate of $(0.36). This represents a remarkable turnaround from the $(0.32) per share loss reported in the same period last year. Revenue also exceeded expectations, coming in at $172.9 million, beating the analyst consensus estimate of $139.4 million by 24.02%. The strong performance marks a 12.93% increase in sales compared to the previous year. Additionally, 10x Genomics achieved a gross margin of 72% and reported a net income of $34.5 million for Q2, demonstrating its ability to drive both top-line growth and profitability.

Adding to the positive sentiment, 10x Genomics announced plans to acquire Scale Biosciences, a move that could potentially expand its market presence and technological capabilities in single-cell analysis. The company also provided an optimistic outlook for the third quarter of 2025, projecting revenue in the range of $140 million to $144 million. This combination of strong financial results, strategic expansion, and positive future guidance likely contributed to the stock's after-hours rally, as investors responded favorably to the company's growth trajectory and improved market position.